• For the base case scenario, input parameters for the MUHC unit (bed size, type of syringes) were used. As such, these results represent the estimated budget impact of moving from nonsafety syringe and vial to a passive-safety insulin pen device.
• Additionally, nurse researchers from the McGill University Health Centre (MUHC) conducted a pilot study in a 52-bed unit to quantify this impact in a local context. This study was completed independently, and results were shared for the purpose of this budget impact model.
• Costs for the volume of insulin dispensed, injection supplies, needlestick injury (NSI) management, and nursing labour were obtained from literature and study pilot data.
• The results from the literature search and the study pilot served as the inputs to an economic model, developed in Excel v14.
• Potential benefits of implementing insulin pen devices in acute care settings include reducing the risk of adverse events such as NSI medication errors, and achieving tighter glycemic control as a result of shorter needle length availability (reduction in intramuscular injections and improved adherence).
• Insulin pen devices in the acute care setting may also decrease waste and inefficiencies such as insulin waste and nursing time. The implementation of insulin pen devices in acute care results in cost savings, as well as time savings for nurses that may be re-directed to increased time at the patient bedside. • The aim of this study was to conduct a budget impact analysis to evaluate the economic impact of adopting passive safety-engineered insulin pens (which do not require activation) in the acute care setting, as it relates to patient and healthcare worker safety, and health resource utilization (HRU).
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• Previous published studies demonstrate that insulin pen devices have the potential to improve inpatient management through better glycemic control, increased adherence and improved self-management education.
• Insulin Volume: Data collected from MUHC indicated that upon comparison pre-implementation of pens and post-implementation, the volume of insulin purchased was reduced by 42%. In addition, a 19.7% increase in cost of insulin delivered in pens was applied based on data from MUHC.
• Needlestick Injury: The NSI reduction rate used in the model is based on a pilot study evaluating the effect of an interchange program for insulin pens, and was calculated at 100% [3] . Findings from a separate study demonstrated zero NSI using passive safety, providing additional validation for this input[4].
• Nursing Efficiency: Data collected at MUHC pertaining to the difference in time to administer insulin via a pen versus the traditional vial/syringe were applied. A daily nursing time savings of 31.5 minutes was calculated, and an average hourly rate for nursing was valued at $26.71 (CAD).
• Supply costs: The model considered all impacted supply costs, including the increase in price to move to a safety insulin pen needle, an approximate 37% increase from safety syringe, or 3.5 times increase from non-safety syringes (BD estimates).
• • The prevalence of diabetes mellitus (DM, or diabetes) is increasing, with a predicted 4.2 million people in Canada living with diabetes by 2020[1].
• Addressing diabetes cost the Canadian healthcare system and the Canadian economy $11.7 billion in 2010, and if diabetes incidence follows current trends, the economic burden will reach $16 billion by 2020.
• Diabetes is a common co-morbidity among hospitalized patients and maintaining glycemic control among hospitalized patients both during their stay, as well as after they are discharged is imperative [2] . One potential intervention to reach this goal is the use of insulin pen devices in both the outpatient and inpatient setting.
• Insulin administration in the acute care setting is an integral component of inpatient diabetes management. The current method of administration in acute care settings is by using a vial and syringe (safety-engineered syringe requiring activation, or non-safety syringe). 
